Apellis Pharmaceuticals Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Apellis Pharmaceuticals APLS, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in APLS usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Apellis Pharmaceuticals. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 38% leaning bullish and 61% bearish. Among these notable options, 7 are puts, totaling $273,449, and 11 are calls, amounting to $1,430,825.

What's The Price Target?

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $100.0 for Apellis Pharmaceuticals over the recent three months.

Volume & Open Interest Trends

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Apellis Pharmaceuticals's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apellis Pharmaceuticals's whale activity within a strike price range from $40.0 to $100.0 in the last 30 days.

Apellis Pharmaceuticals 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Having examined the options trading patterns of Apellis Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance

Current Position of Apellis Pharmaceuticals

• With a volume of 2,445,993, the price of APLS is up 0.5% at $59.91.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 43 days.

Expert Opinions on Apellis Pharmaceuticals

5 market experts have recently issued ratings for this stock, with a consensus target price of $63.8.

• Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Apellis Pharmaceuticals, targeting a price of $56.
• Consistent in their evaluation, an analyst from Raymond James keeps a Strong Buy rating on Apellis Pharmaceuticals with a target price of $67.
• An analyst from Oppenheimer persists with their Outperform rating on Apellis Pharmaceuticals, maintaining a target price of $75.
• In a cautious move, an analyst from Wells Fargo downgraded its rating to Equal-Weight, setting a price target of $54.
• Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Apellis Pharmaceuticals with a target price of $67.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Apellis Pharmaceuticals with Benzinga Pro for real-time alerts.